RxDoctor Payments Data

Tim Baker, MD

Internal Medicine · Washington, MONPI 1760596134

Payments from drug & device makers

$817in general payments, 2019–2025

Across 41 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$254
  • Merck$129
  • Astellas Pharma US Inc$85
  • Sanofi-aventis U.S. LLC$80
  • Novo Nordisk$80
  • Boehringer Ingelheim$50
  • plus $139 from 7 others

What the payments were for

  • Speaking & faculty fees$8010%
  • Food & beverage$64178%
  • Education$9712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$817 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$52,288
Medicare patients
157
Services billed
2,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$223,825
JardianceEmpagliflozin163$185,412
EliquisApixaban146$152,375
AbrysvoRsv Vacc, Pref A And Pref B/Pf421$128,929
TrulicityDulaglutide72$104,043
JanuviaSitagliptin Phosphate73$86,549
XareltoRivaroxaban76$81,626
MounjaroTirzepatide48$75,283
Tresiba Flextouch U-100Insulin Degludec62$48,974
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$33,805
LivaloPitavastatin Calcium33$25,778
MyrbetriqMirabegron30$24,509
Breo ElliptaFluticasone/Vilanterol29$18,480
InvokanaCanagliflozin13$18,243
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$17,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$17$285,278581 claims
Novo NordiskOzempic$80$223,825117 claims
Boehringer IngelheimJardiance$50$185,412163 claims
Lilly USA, LLCTrulicity, Mounjaro$41$179,326120 claims
Johnson & JohnsonXarelto, Invokana$28$99,86989 claims
MerckJanuvia$129$86,54973 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Anoro Ellipta$12$60,867120 claims
Kowa Pharmaceuticals America, Inc.Livalo$13$25,77833 claims
Astellas Pharma US IncMyrbetriq$85$24,50930 claims
Sanofi-aventis U.S. LLCLantus$80$4,13718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →